myTomorrows
myTomorrows is a global health technology platform that connects patients with serious diseases to clinical trials and expanded access programs across 134+ countries, serving BioPharma clients through AI-powered trial matching, EAP management, and real-world data services while offering free patient navigation.
- Company typePrivate
- Founded2012
- HeadquartersAmsterdam, Netherlands
- Headcount101–250
- GTM typeB2B
- OfferingServices
What myTomorrows does
myTomorrows is a global health technology platform founded in 2012 and headquartered in Amsterdam, Netherlands, that connects patients with serious diseases to clinical trials and expanded access programs (EAPs) worldwide. The company operates a three-sided marketplace serving patients and caregivers (free), healthcare professionals (free), and BioPharma companies (paid), with a footprint spanning 134+ countries and 16,900+ patients served. Core products include an AI-powered treatment search engine that aggregates ClinicalTrials.gov, ISCRTN, and EU Clinical Trials Register data; a Patient Navigation service staffed by medically-trained navigators; an Expanded Access Program (EAP) management platform; and Real-World Data services. Proprietary AI technology includes an LLM-based clinical trial matching tool claiming 98% precision accuracy and an EHR-integrated pre-screening engine deployed at partner sites such as Clínica Universidad de Navarra.
myTomorrows generates revenue through B2B services to BioPharma companies including clinical trial recruitment support, full-service Expanded Access Program management (regulatory submissions, drug supply coordination, safety reporting), and real-world data collection for regulatory and payor objectives. The company also supplies medicinal products for expanded access programs and similar regulatory pathways to pharmacies, hospitals, and distributors. Services to patients and healthcare professionals are provided free of charge, with the freemium model functioning as a top-of-funnel acquisition channel for enterprise contracts.
The company is regulated under European Manufacturing & Importation Authorization and Wholesale Distributor Authorization from the Dutch Ministry of Health (VWS), holding GMP and GDP compliance certifications, plus ISO 27001, SOC 2 Type I, and GDPR certifications. Strategic partnerships include integrations with b.well Connected Health (2.4M providers), Clínica Universidad de Navarra (200+ trials), Rare Disease Research (SE US), and Sentynl Therapeutics (Managed Access Programs). The company received a €25 million growth investment from Avego Healthcare Capital in November 2025 and was selected for the AWS Pioneers Project 2026.
myTomorrows firmographics
Firmographics- Name
- myTomorrows
- Legal name
- Impatients N.V.
- Website
- https://mytomorrows.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- myTomorrows is a global health technology platform that connects patients with serious diseases to clinical trials and expanded access programs across 134+ countries, serving BioPharma clients through AI-powered trial matching, EAP management, and real-world data services while offering free patient navigation.
- Ownership category
- akta.pro rank
myTomorrows industry classification
Industry- Product category
- Clinical Trial Access Platform
- NAICS
- Computer Systems Design and Related Services (54151)
- SIC
- Services-Health Services (8000), Services-Computer Programming, Data Processing, Etc. (7370)
- akta.pro primary industry
- Randomization & Trial Supply Management (RTSM/IRT/IVRS/IWRS) (HLACAOAC)
- akta.pro secondary industry
- Healthcare Outcomes & Real-World Evidence (RWE) Analytics (BPAHALAN)
Keywords
Where myTomorrows is headquartered
LocationHeadquarters
- HQ city
- Amsterdam
- HQ country
- Netherlands
- HQ region
- Europe
Offices1 record
Markets served
myTomorrows business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain
Revenue model
- BioPharma services - Clinical trial recruitment: myTomorrows provides patient recruitment support services to pharmaceutical companies for clinical trials, helping reduce recruitment timelines and screening costs
- Expanded Access Program management: Full-service EAP management services for BioPharma including program design, regulatory compliance, drug supply, and distribution
- Real-World Data services: Specialized RWD services for pharmaceutical companies to collect observational data supporting regulatory and payor objectives
- Medicinal product supply for expanded access: Supply of medicinal products for expanded access programs, similar regulatory pathways, or off-label use to pharmacies, hospitals, and local distributors
- Patient platform services: Free services provided to patients and healthcare professionals for discovering and accessing treatments in development
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Freemium | Monthly | Free platform access for patients and healthcare professionals |
| Other | Multi-year contract | Paid BioPharma services |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels7 records
myTomorrows product offering
Product offeringCore offering
myTomorrows operates a global platform that connects patients with serious diseases and their physicians to treatments in development, including clinical trials and expanded access programs, supported by medically-trained Patient Navigators. For BioPharma clients, the company provides clinical trial recruitment services, full-service Expanded Access Program (EAP) management, a purpose-built Expanded Access Management Platform, and Real-World Data services, underpinned by an AI-powered clinical trial matching tool with reported 98% precision accuracy.
Product overview
myTomorrows operates as a unified health technology platform connecting patients, physicians, and bioPharma companies for pre-approval treatment access. The platform consists of an AI-powered Treatment Search Engine that searches global clinical trial databases, combined with Patient Navigation Services staffed by medically-trained navigators. For bioPharma clients, the company offers Clinical Trial Recruitment Services, Expanded Access Services, an Expanded Access Management Platform, Real-World Data Services, and Managed Access Programs. Key AI features include an AI Clinical Trial Matching Tool achieving 98% precision accuracy and AI-Assisted Patient-Trial Matching integrated into hospital EHR systems. The platform supports patients across 134 countries and early access to over 10,000 therapies in development.
Differentiator
Problem solved
Functional benefit
Products and services
- AI Treatment Search Engine AI-powered search engine that enables patients and physicians to discover clinical trials and expanded access programs across multiple global registries. Provided to patients and healthcare professionals at no cost via the myTomorrows platform.
- Patient Navigation Services Personalized support service staffed by medically-trained Patient Navigators who guide patients and caregivers through treatment discovery, eligibility assessment, and access to pre-approval treatments. Free of charge to patients.
- Clinical Trial Recruitment Services Patient recruitment support services for clinical trials, helping pharmaceutical sponsors reduce recruitment timelines, lower screening costs, and enroll more diverse patient populations.
- Expanded Access Services Full-service Expanded Access Program management for BioPharma clients covering program design, regulatory compliance, physician engagement, drug supply coordination, and safety reporting.
- Expanded Access Management Platform Purpose-built technology platform that supports BioPharma expanded access operations with workflow management, compliance, traceability, and regulatory coordination.
- Real-World Data Services Specialized services that collect and analyze Real-World Data from expanded access programs to support BioPharma regulatory and payor objectives.
- Managed Access Program Program management service for BioPharma companies to provide patient access to treatments outside of clinical trials, including compassionate use and named patient programs.
- Medicinal Product Supply for Expanded Access Transactional supply of investigational or authorized medicinal products for expanded access, similar regulatory pathways, or off-label use to pharmacies, hospitals, and local distributors, operated under GMP/GDP compliance.
Quantifiable outcome
- 500% revenue growth over four years
- +3 more outcomes
Companies that use myTomorrows
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles3 records
myTomorrows technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability4 records
Feature4 records
myTomorrows partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered flagship and core.
- b.well Connected HealthflagshipStrategic partnership to launch AI-driven clinical trial matching platform combining b.well's FHIR-based health data network (2.4M providers, 330 health plans, multiple state HIEs) with myTomorrows' AI-powered pre-screening engine. Aims to automate patient matching, reduce recruitment timelines, lower screening costs, and enroll diverse populations
- Rare Disease ResearchcorePartnership to improve rare disease patient identification and referral into clinical trials through structured referral pathway. Initially supporting research sites in Georgia, Florida, and North Carolina, enabling referring physicians to submit qualified referrals directly to RDR site teams
- CUNcorePartnership on AI-assisted patient trial matching technology development
- Clínica Universidad de Navarra (CUN)coreFirst large-scale site partnership in Spain implementing AI-assisted patient-trial matching across CUN's portfolio of 200+ active clinical trials. System uses LLM to analyze clinical variables integrated directly into CUN's EHR and CTMS. Includes CUN-branded referral platform for external physicians
- Amazon Web Services (AWS)coreSelected for AWS Pioneers Project 2026, recognizing the company's AI innovation in healthcare for advancing Europe's competitiveness through purposeful innovation
- Sentynl TherapeuticscoreSentynl transitioned its Managed Access Program to myTomorrows to improve access to treatments for rare diseases, including ultra-rare conditions like Hutchinson-Gilford Progeria Syndrome. Partnership aims to expand program reach and improve access to therapies
Scale indicators8 records
Recent moves6 records
Expansion highlights5 records
myTomorrows competitors and assessment
Company assessmentDirect peers
- Clara Health: Patient navigation and clinical trial concierge service for patients and sponsors; overlaps with myTomorrows' Patient Navigator offering and sponsor recruitment business model.
- Mendel: AI platform that structures clinical data and matches patients to trials and cohorts; comparable technology (LLM + clinical NLP) and sells to both health systems and life sciences sponsors.
- Massive Bio: AI-driven clinical trial matching and patient recruitment for oncology; competes head-to-head with myTomorrows on pharma-sponsored patient recruitment, particularly in the US, and serves a similar BioPharma buyer.
- Deep 6 AI: AI clinical trial matching platform that mines unstructured EHR data to match patients to trials; directly comparable technology approach (LLM on clinical notes) and end customers (health systems and sponsors).
- Antidote: Patient-facing clinical trial matching and digital engagement platform acquired by Thread; competes with myTomorrows on patient recruitment funnels and sponsor recruitment services.
Broad incumbents
- Veeva Systems: Life sciences cloud platform covering clinical, regulatory and commercial workflows; a broad incumbent in the same sponsor IT budget pools myTomorrows targets with its recruitment and EAP services.
- ICON plc: Major global CRO with technology-enabled patient recruitment and post-approval access programs; competing incumbent for enterprise BioPharma contracts myTomorrows targets.
- Parexel International: Global CRO offering patient recruitment, real-world evidence and expanded access services; competes with myTomorrows on the BioPharma services stack, particularly around EAP and RWD.
- IQVIA: Largest global CRO with its own AI-driven trial recruitment and RWD capabilities; represents the broad incumbent that myTomorrows must compete against for enterprise BioPharma master agreements.
- Medidata Solutions: Dassault Systèmes-owned clinical trial technology platform (Rave, eCOA, RTSM); a broad incumbent whose trial informatics stack competes with myTomorrows on sponsor technology spend.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
myTomorrows social profiles
Digital presencemyTomorrows compliance and trust
Trust signalCompliance4 records
myTomorrows financial estimates
Financial estimateRevenue estimate
Valuation estimate
myTomorrows leadership team
Management profileNumber of profiles
Profiles7 records
myTomorrows funding detail
Funding detailFunding overview
Funding rounds6 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
myTomorrows M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about myTomorrows
What does myTomorrows do?
myTomorrows operates a global platform that connects patients with serious diseases and their physicians to treatments in development, including clinical trials and expanded access programs, supported by medically-trained Patient Navigators. For BioPharma clients, the company provides clinical trial recruitment services, full-service Expanded Access Program (EAP) management, a purpose-built Expanded Access Management Platform, and Real-World Data services, underpinned by an AI-powered clinical trial matching tool with reported 98% precision accuracy.
Is myTomorrows a public or private company?
myTomorrows is a private company. It is classified as venture growth investor backed and is currently operating.
When was myTomorrows founded?
myTomorrows was founded in 2012. It employs 101 to 250 people.
Where is myTomorrows based?
myTomorrows is headquartered in Amsterdam, Netherlands, in the Europe region.
How does myTomorrows make money?
Five revenue lines are on record. BioPharma services - Clinical trial recruitment is the primary driver. The others are expanded Access Program management, real-World Data services, medicinal product supply for expanded access and patient platform services.
Who are myTomorrows's main competitors?
Direct peers on record are Clara Health, Mendel, Massive Bio, Deep 6 AI and Antidote. Broad incumbents are Veeva Systems, ICON plc, Parexel International, IQVIA and Medidata Solutions.
Does myTomorrows have an API?
No public API is recorded for myTomorrows.
What industry is myTomorrows in?
myTomorrows's product category is Clinical Trial Access Platform. Its primary akta.pro industry code is HLACAOAC, Randomization & Trial Supply Management (RTSM/IRT/IVRS/IWRS), with a secondary code of BPAHALAN, Healthcare Outcomes & Real-World Evidence (RWE) Analytics. Its NAICS code is 54151 and its SIC code is 8000.